Gyre Therapeutics (GYRE) Institutional Ownership $7.81 +0.17 (+2.23%) Closing price 04:00 PM EasternExtended Trading$7.82 +0.01 (+0.13%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Gyre Therapeutics (NASDAQ:GYRE)CurrentInstitutional OwnershipPercentage23.99%Number ofInstitutional Buyers(last 12 months)16TotalInstitutional Inflows(last 12 months)$4.69MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$574.17K Get GYRE Insider Trade Alerts Want to know when executives and insiders are buying or selling Gyre Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GYRE Institutional Buying and Selling by Quarter Gyre Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails6/27/2025Goldman Sachs Group Inc.16,147$125K0.0%-38.8%0.017% 5/16/2025Goldman Sachs Group Inc.16,147$125K0.0%-38.8%0.017% 5/14/2025Advantage Alpha Capital Partners LP13,663$105K0.0%+54.0%0.015% 5/13/2025American Century Companies Inc.23,825$184K0.0%N/A0.025% 5/9/2025Charles Schwab Investment Management Inc.111,416$860K0.0%-2.7%0.119% 5/2/2025SBI Securities Co. Ltd.123,629$954K0.0%+22.1%0.132% 4/29/2025Bank of New York Mellon Corp16,492$127K0.0%+18.7%0.018% 4/7/2025 GAMMA Investing LLC1,822$140K0.0%+15,083.3%0.002% 2/17/2025Bank of America Corp DE6,937$84K0.0%+40.4%0.007% 2/14/2025Northern Trust Corp103,382$1.25M0.0%+9.1%0.111% Get the Latest News and Ratings for GYRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025Barclays PLC10,543$128K0.0%+13.5%0.011% 2/13/2025Wells Fargo & Company MN4,016$49K0.0%+29.4%0.004% 2/11/2025Advantage Alpha Capital Partners LP8,873$107K0.0%-66.7%0.009% 2/6/2025Charles Schwab Investment Management Inc.114,566$1.39M0.0%+0.8%0.123% 2/6/2025SBI Securities Co. Ltd.101,239$1.23M0.0%N/A0.108% 2/4/2025Bank of New York Mellon Corp13,896$168K0.0%+11.1%0.015% 11/19/2024Barclays PLC9,288$116K0.0%+281.8%0.010% 11/16/2024Geode Capital Management LLC303,647$3.81M0.0%+16.9%0.325% 11/15/2024Barclays PLC9,288$116K0.0%+281.8%0.010% 11/15/2024State Street Corp104,490$1.31M0.0%+8.8%0.112% 11/13/2024FMR LLC3,742$47K0.0%N/A0.004% 11/13/2024Advantage Alpha Capital Partners LP26,634$334K0.1%N/A0.029% 11/12/2024Charles Schwab Investment Management Inc.113,648$1.43M0.0%+392.2%0.122% 8/14/2024Marshall Wace LLP10,720$128K0.0%-58.0%0.013% 8/9/2024Renaissance Technologies LLC13,900$166K0.0%N/A0.016% 8/9/2024WINTON GROUP Ltd18,467$220K0.0%N/A0.022% 8/1/2024Rhumbline Advisers10,291$123K0.0%N/A0.012% 7/26/2024Bank of New York Mellon Corp18,266$218K0.0%N/A0.021% 5/10/2024Vanguard Group Inc.195,098$3.41M0.0%-1.5%0.228% (Data available from 1/1/2016 forward) GYRE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GYRE shares? During the previous two years, 19 institutional investors and hedge funds held shares of Gyre Therapeutics. The most heavily invested institutionals were Geode Capital Management LLC ($3.81M), Vanguard Group Inc. ($3.41M), State Street Corp ($1.31M), Northern Trust Corp ($1.25M), SBI Securities Co. Ltd. ($954K), Charles Schwab Investment Management Inc. ($860K), and WINTON GROUP Ltd ($220K).Learn more on Gyre Therapeutics' institutional investors. What percentage of Gyre Therapeutics' stock is owned by institutional investors? 23.99% of Gyre Therapeutics' stock is owned by institutional investors. Learn more on GYRE's institutional investor holdings. Which institutional investors have been buying Gyre Therapeutics' stock? Of the 16 institutional investors that purchased Gyre Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: SBI Securities Co. Ltd. ($123.63K), Charles Schwab Investment Management Inc. ($91.48K), Geode Capital Management LLC ($43.84K), Advantage Alpha Capital Partners LP ($31.42K), American Century Companies Inc. ($23.83K), Bank of New York Mellon Corp ($22.25K), and WINTON GROUP Ltd ($18.47K). How much institutional buying is happening at Gyre Therapeutics? Institutional investors have bought a total of 401,298 shares in the last 24 months. This purchase volume represents approximately $4.69M in transactions. Which of Gyre Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Gyre Therapeutics stock in the last 24 months: Goldman Sachs Group Inc. ($20.48K), Advantage Alpha Capital Partners LP ($17.76K), Marshall Wace LLP ($14.82K), and Charles Schwab Investment Management Inc. ($3.15K). How much institutional selling is happening at Gyre Therapeutics? Institutional investors have sold a total of 56,213 shares in the last 24 months. This volume of shares sold represents approximately $574.17K in transactions. Related Companies Alvotech Institutional Ownership Mirum Pharmaceuticals Institutional Ownership Catalyst Pharmaceuticals Institutional Ownership Amneal Pharmaceuticals Institutional Ownership NewAmsterdam Pharma Institutional Ownership Ultragenyx Pharmaceutical Institutional Ownership Organon & Co. Institutional Ownership Apellis Pharmaceuticals Institutional Ownership ImmunityBio Institutional Ownership Xenon Pharmaceuticals Institutional Ownership This page (NASDAQ:GYRE) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredIs America’s Everything Bubble About to Burst?On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
